Numerically, there were 15 allograft failures in the anti-TNFα group (17.2%, of whom 13/15 were complete thrombosis) and 32 in the SOC group (21.5%, of whom 19/32 were complete thrombosis) at 3 years. The gene discussed is TNF; the disease is deep vein thrombosis.